Medica Coverage Policy

Policy Name: Vestibular Evoked Myogenic Potentials (VEMP)
Current Policy Effective Date: 1/1/2016

Important Information – Please Read Before Using This Policy

These services may or may not be covered by all Medica plans. Please refer to the member’s plan document for specific coverage information. If there is a difference between this general information and the member’s plan document, the member’s plan document will be used to determine coverage. With respect to Medicare, Medicaid and MinnesotaCare members, this policy will apply unless these programs require different coverage. Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Medica coverage policy may call the Medica Provider Service Center toll-free at 1-800-458-5512.

Medica coverage policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care and treatment.

Coverage Policy
Vestibular evoked myogenic potential testing is investigative and therefore NOT COVERED.

Description
Vertigo and dizziness are common symptoms reported by patients during visits to their doctors. These symptoms can arise from a peripheral vestibular disorder (a dysfunction of the balance organs of the inner ear) or central vestibular disorder (dysfunction of one or more parts of the central nervous system that helps process balance and spatial information). Symptoms may impact a person’s ability to change positions without dizziness or imbalance.

Vestibular evoked myogenic potential (VEMP) testing, also known as click evoked neurogenic vestibular potential testing, is used to ascertain whether vestibular organs and associated nerves are functioning normally. The vestibular organs are stimulated with sound, which activates muscle responses, and results are recorded. VEMP testing is noninvasive and utilizes skin surface electrodes and earphones. This testing has been proposed for use in the diagnosis of Benign Paroxysmal Positional Vertigo (BPPV), Ménière's disease and some other neurologic disorders.

FDA Approval
VEMP testing is a procedure and not subject to Food and Drug Administration (FDA) regulation; however, any medical devices used as part of the procedure may be subject to FDA regulation. The FDA has not approved any device specific to VEMP. There are multiple categories of devices cleared by the FDA that could be used for VEMP testing, including auditory evoked response stimulators, represented by product code GWJ.

Prior Authorization
Prior authorization is not applicable. Claims for this service are subject to retrospective review and denial of coverage, as investigative services are not eligible for reimbursement.
Coding Considerations
Use the current applicable CPT/HCPCS code(s). The following codes are included below for informational purposes only, and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

CPT Codes:
• 92700 – unlisted otorhinolaryngological service or procedure

Original Effective Date: 1/1/2016
Re-Review Date(s):